111 related articles for article (PubMed ID: 18575956)
1. Comparison of time-action profiles of insulin glargine and NPH insulin in normal and diabetic dogs.
Mori A; Sako T; Lee P; Motoike T; Iwase K; Kanaya Y; Fukuta H; Mizutani H; Arai T
Vet Res Commun; 2008 Oct; 32(7):563-73. PubMed ID: 18575956
[TBL] [Abstract][Full Text] [Related]
2. Insulin glargine versus NPH insulin in patients with type 1 diabetes.
Ratner R
Drugs Today (Barc); 2003 Nov; 39(11):867-76. PubMed ID: 14702132
[TBL] [Abstract][Full Text] [Related]
3. [Insulin glargine improves fasting blood glucose levels in prepubertal children with unsatisfactorily controlled type 1 diabetes].
Mianowska B; Szadkowska A; Czerniawska E; Pietrzak I; Bodalski J
Pediatr Endocrinol Diabetes Metab; 2007; 13(4):189-93. PubMed ID: 18042313
[TBL] [Abstract][Full Text] [Related]
4. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime.
Rossetti P; Pampanelli S; Fanelli C; Porcellati F; Costa E; Torlone E; Scionti L; Bolli GB
Diabetes Care; 2003 May; 26(5):1490-6. PubMed ID: 12716810
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique.
Scholtz HE; Pretorius SG; Wessels DH; Becker RH
Diabetologia; 2005 Oct; 48(10):1988-95. PubMed ID: 16160867
[TBL] [Abstract][Full Text] [Related]
6. Replacing Insulin Glargine with Neutral Protamine Hagedorn (NPH) Insulin in a Subpopulation of Study Subjects in the Action to Control Cardiovascular Risk in Diabetes (ACCORD): Effects on Blood Glucose Levels, Hypoglycemia and Patient Satisfaction.
Berard L; Cameron B; Woo V; Stewart J
Can J Diabetes; 2015 Aug; 39(4):296-301. PubMed ID: 25819531
[TBL] [Abstract][Full Text] [Related]
7. Time-action profiles of insulin detemir in normal and diabetic dogs.
Sako T; Mori A; Lee P; Oda H; Saeki K; Miki Y; Kurishima M; Mimura K; Nozawa S; Mizutani H; Makino Y; Ishioka K; Arai T
Res Vet Sci; 2011 Jun; 90(3):396-403. PubMed ID: 20708207
[TBL] [Abstract][Full Text] [Related]
8. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes.
Rosenstock J; Dailey G; Massi-Benedetti M; Fritsche A; Lin Z; Salzman A
Diabetes Care; 2005 Apr; 28(4):950-5. PubMed ID: 15793205
[TBL] [Abstract][Full Text] [Related]
9. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes.
Raskin P; Klaff L; Bergenstal R; Hallé JP; Donley D; Mecca T
Diabetes Care; 2000 Nov; 23(11):1666-71. PubMed ID: 11092290
[TBL] [Abstract][Full Text] [Related]
10. Comparison of insulin glargine and NPH insulin in the treatment of type 2 diabetes: a review of clinical studies.
Duckworth W; Davis SN
J Diabetes Complications; 2007; 21(3):196-204. PubMed ID: 17493554
[TBL] [Abstract][Full Text] [Related]
11. Nocturnal glucose metabolism after bedtime injection of insulin glargine or neutral protamine hagedorn insulin in patients with type 2 diabetes.
Linn T; Fischer B; Soydan N; Eckhard M; Ehl J; Kunz C; Bretzel RG
J Clin Endocrinol Metab; 2008 Oct; 93(10):3839-46. PubMed ID: 18611975
[TBL] [Abstract][Full Text] [Related]
12. Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride.
Eliaschewitz FG; Calvo C; Valbuena H; Ruiz M; Aschner P; Villena J; Ramirez LA; Jimenez J;
Arch Med Res; 2006 May; 37(4):495-501. PubMed ID: 16715577
[TBL] [Abstract][Full Text] [Related]
13. [Comparison between basal insulin glargine and NPH insulin in patients with diabetes type 1 on conventional intensive insulin therapy].
Pesić M; Zivić S; Radenković S; Velojić M; Dimić D; Antić S
Vojnosanit Pregl; 2007 Apr; 64(4):247-52. PubMed ID: 17580534
[TBL] [Abstract][Full Text] [Related]
14. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients.
Riddle MC; Rosenstock J; Gerich J;
Diabetes Care; 2003 Nov; 26(11):3080-6. PubMed ID: 14578243
[TBL] [Abstract][Full Text] [Related]
15. Comparison of once-daily glargine insulin with twice-daily NPH/regular insulin for control of hyperglycemia in inpatients after cardiovascular surgery.
Yeldandi RR; Lurie A; Baldwin D
Diabetes Technol Ther; 2006 Dec; 8(6):609-16. PubMed ID: 17109592
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.
Lepore M; Pampanelli S; Fanelli C; Porcellati F; Bartocci L; Di Vincenzo A; Cordoni C; Costa E; Brunetti P; Bolli GB
Diabetes; 2000 Dec; 49(12):2142-8. PubMed ID: 11118018
[TBL] [Abstract][Full Text] [Related]
17. A randomized trial comparing the rate of hypoglycemia--assessed using continuous glucose monitoring--in 125 preschool children with type 1 diabetes treated with insulin glargine or NPH insulin (the PRESCHOOL study).
Danne T; Philotheou A; Goldman D; Guo X; Ping L; Cali A; Johnston P
Pediatr Diabetes; 2013 Dec; 14(8):593-601. PubMed ID: 23730996
[TBL] [Abstract][Full Text] [Related]
18. Time-action profiles of insulin degludec in healthy dogs and its effects on glycemic control in diabetic dogs.
Oda H; Mori A; Ishii S; Shono S; Onozawa E; Sako T
J Vet Med Sci; 2018 Nov; 80(11):1720-1723. PubMed ID: 30305465
[TBL] [Abstract][Full Text] [Related]
19. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group.
Rosenstock J; Park G; Zimmerman J;
Diabetes Care; 2000 Aug; 23(8):1137-42. PubMed ID: 10937511
[TBL] [Abstract][Full Text] [Related]
20. Time-action profile of the long-acting insulin analogue insulin glargine in comparison to NPH insulin in Japanese volunteers.
Rave K; Nosek L; Heinemann L; Frick A; Becker R
Diabetes Metab; 2003 Sep; 29(4 Pt 1):430-1. PubMed ID: 14526272
[No Abstract] [Full Text] [Related]
[Next] [New Search]
